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ABSTRACT 
Although the most important prognostic and predictive marker in colorectal 
cancer is tumor cells in lymph nodes, ~30% of patients who are node-negative 
die from occult metastases.  Molecular staging employing specific markers and 
sensitive detection technologies has emerged as a powerful platform to assess 
prognosis in node-negative colon cancer.  Integrating molecular staging into 
algorithms that individualize patient management will require validation and the 
definition of relationships between occult tumor cells, prognosis, and responses 
to chemotherapy. 
INTRODUCTION 
Clinicopathological staging remains the most important prognostic marker of 
survival and predictive marker of therapeutic response for most cancer patients.  
Despite its importance, clinicopathological staging remains imperfect, and 
identification of patients at greatest risk for disease recurrence or deriving 
optimum benefit from therapy has eluded definition for most tumors.  
Emergence of platform technologies to interrogate genomic and post-genomic 
structure and function has provided an explosion of new diagnostic markers and 
therapeutic targets with the potential to individualize cancer prevention, 
detection and cure.  Despite these exponential scientific advances, clinical 
translation has substantially lagged, in part, reflecting the absence of the 
evidence base positioning these new technologies in diagnostic and 
therapeutic management algorithms.   
Employing colon cancer as a clinical model, this review will explore the 
application of molecular staging to prognosis and prediction, to individualize 
patient management.  Specifically, the ability of molecular staging to quantify 
occult metastases in regional lymph nodes, predict disease recurrence, and 
identify patients who could benefit from adjuvant chemotherapy will be 
examined.  A conceptual framework for integrating molecular staging of lymph 
nodes into a reflex diagnostic paradigm incorporating standard 
clinicopathological indices and molecular signatures from primary tumors that 
optimizes individualization of patient management will be discussed.  The 
objective of this review is to demonstrate for the clinician the potential power of 
emerging molecular technologies for the diagnostic and therapeutic 
management of patients with cancer.  It is anticipated that this review will 
provide practicing physicians with an appreciation of those molecular 
technologies, their emerging role in diagnostic and therapeutic algorithms, and 
the evidence supporting their utility in patient-centric management algorithms. 
COLORECTAL CANCER 
Cancer of the colorectum is the 4th most common malignancy, with ~150,000 
new cases annually, and the 2nd most common cause of cancer-related death 
[1].  Colorectal cancer causes ~10% of cancer-related deaths in the U.S., and 
mortality approaches ~50% [1-3].  Death from colorectal cancer reflects 
metastatic disease: ~20% of patients have unresectable metastases at the time 
of initial evaluation while more than 30% of patients will develop metastatic 
disease during the course of their illness [2-5].  Surgery continues to be the 
mainstay of treatment, with the greatest influence on survival.  However, while 
presumptively curative surgery excises all obvious tumor, occult metastases 
conspire to produce disease recurrence [1-3,6-9].  Rates of disease recurrence 
nominally extend from 10% for tumors confined to mucosa (stage I) to more than 
50% for tumors with metastases to regional lymph nodes (stage III) [1-3,6-19]. 
A.  Staging as a prognostic marker.  The most significant prognostic marker of 
colorectal cancer survival is tumor cells in regional lymph nodes [1-6,9,20-24].  
Although staging by histology remains the standard, imprecision reflects 
limitations inherent to the method [2,5,24].  Microscopy has restricted sensitivity, 
with detection limits of 1 cancer cell in about 200 normal cells [25].  Also, 
histology typically reviews less than 0.1% of biopsied tissue, producing sampling 
error, since more than 99.9% of available tissue is not examined and cancer cells 
do not distribute homogenously [4,5,25].  These restrictions imposed by 
microscopy are brought into specific relief by considering the rate of post-
operative cancer recurrence.  Stage I and II (node-negative) disease, limited to 
the bowel wall without microscopic detection of metastases in lymph nodes, 
should be completely cured by surgical resection.  Yet, up to 30% of stage I and 
50% of stage II patients develop recurrent disease [2,3,5,24].  Stage III patients, in 
whom all obvious cancer, including that metastasized to regional lymph nodes, 
is excised, exhibit recurrence rates of up to 70% [2,10,12-15,17-19,26,27].  
Differences in reported recurrence rates in patients with node-negative disease 
likely reflect the combination of patients who are truly node-negative and those 
with stage III or IV disease that escape identification by histology 
[2,4,5,12,21,28,29]. 
B.  Staging as a predictive marker.  Disease stage in colorectal cancer not only 
determines patient prognosis, but also predicts which patients will derive benefit 
from adjuvant therapy.  Chemotherapy administered after presumptively 
curative surgery to stage III colon cancer patients improves survival, enhancing 
time-to-recurrence up to 40% and overall survival up to 30% [6,20,30-36].  
Moreover, the recent introduction of biologically targeted individualized 
therapies, such as monoclonal antibodies aimed at key signaling molecules 
including VEGF and EGF receptors, has further increased 5 year median and 
overall survival in patients with widely metastatic disease, from 7% to more than 
30% [37].  In striking contrast, the activity of adjuvant chemotherapies in patients 
with node-negative colon cancer is unclear, with only minimal impact on 
survival in some clinical trials [2,3,6,9,20,22,23,38].  This indeterminate therapeutic 
benefit is reflected in the evolution of treatment guidelines, some of which 
advocate adjuvant chemotherapy for patients with poor clinicopathologic 
features including lymphovascular invasion, deep penetration into the bowel 
wall, or extension to surrounding structures [9,39-41].  In that context, 
unpredictable responses to adjuvant therapy in node-negative patients may 
reflect heterogeneity of occult lymph node metastases [4,5,21,24,42-44].  Thus, 
methods that detect occult metastases in lymph nodes may better identify 
node-negative patients who would best benefit from adjuvant therapy [6,37]. 
MOLECULAR STAGING 
Histology remains the most important procedure for staging patients with colon 
cancer, reflecting the relationship between tumor cells in regional lymph nodes 
and patient prognosis and prediction [1-6,9,20-23].  However, microscopy 
underestimates the presence of metastases in tissues and about 70% of regional 
lymph nodes that contain metastases have nests of cells below <0.5 cm which 
escape observation [2,3,5,24].  Beyond histopathology, more recently 
developed molecular staging approaches, including coupling disease-specific 
markers with a powerful detection technology like quantitative reverse 
transcriptase-polymerase chain reaction (qRT-PCR), offer a sensitive detection 
system for metastases (Fig. 1) [5,24].  Molecular staging can interrogate the 
whole specimen, avoiding sampling errors, and detect one tumor cell in about 
one million normal cells, overcoming sensitivity limitations [5,24].  Until recently, 
the utility of these molecular approaches for staging patients has been unclear, 
because studies have been burdened by insufficient patient sample size, 
deficient longitudinal follow-up, and heterogeneous analytic approaches.  
Meta-analyses suggest that these molecular approaches offer a diagnostic 
advantage for staging patients with colorectal cancer [4,5,21,29,44,45]. 
A.  GUCY2C: A unique paradigm for molecular staging in colon cancer.  
GUCY2C is one member of a family of enzyme receptors synthesizing guanosine 
3’, 5’ cyclic monophosphate (cyclic GMP; cGMP) from GTP.  This protein is 
specifically expressed by intestinal cells, but not by extra-intestinal tissues [46-55].  
GUCY2C is the receptor for the paracrine hormones uroguanylin and guanylin 
produced locally in the small intestine and colon, respectively.  Their interaction 
with the extracellular ligand binding domain of GUCY2C activates the 
intracellular catalytic domain, initiating cGMP synthesis [51,54,56-62].  GUCY2C 
regulates epithelial cell cycle kinetics, DNA damage sensing and repair, 
metabolic signaling, and epithelial-mesenchymal cross-talk directing 
homeostasis along the dynamic crypt-surface axis [63-75].  Of significance, 
guanylin and uroguanylin expression is universally eliminated early in neoplastic 
transformation [76-80].  In close agreement, silencing GUCY2C signaling 
increases tumors in mouse models of genetic and carcinogen-based 
tumorigenesis, reflecting dysregulation of proliferation and chromosomal 
instability [66].  Indeed, GUCY2C is a tumor suppressor organizing the crypt-
surface axis whose dysregulation reflecting loss of paracrine hormone expression 
contributes to intestinal neoplasia [64-67,71]. 
Beyond its role as a tumor suppressor, GUCY2C exhibits expression 
characteristics that make it uniquely suitable as a molecular marker of 
colorectal cancer metastases in extra-intestinal tissues.  GUCY2C has been 
identified in all samples of normal intestine, but not in any extra-gastrointestinal 
tissues [42,45,47,48,56].  Further, GUCY2C has been identified in nearly all human 
colorectal tumors, independent of anatomical location or grade, but not in 
extra-gastrointestinal malignancies [42,45,47,48,56,79,81-84].  Moreover, 
GUCY2C expression is amplified in most colorectal tumors, compared to normal 
intestinal tissues [81,85,86].  Thus, expression restricted to intestinal epithelial cells 
in normal physiology, but global excess expression by metastatic cancer cells, 
highlights the potential applicability of GUCY2C to identify occult metastases in 
lymph nodes of patients undergoing staging for colorectal cancer [44]. 
B.  Detection of occult metastases using GUCY2C.  Analyses conducted 
retrospectively suggested that GUCY2C RT-PCR detected occult metastases in 
lymph nodes related to disease recurrence in patients with colorectal cancer 
[45].  These preliminary studies served as the foundation for an appropriately 
powered prospective multicenter analysis of the applicability of GUCY2C, 
detected by qRT-PCR, to detect clinically important occult lymph node 
metastases.  Thus, 257 stage 0-II pN0 colorectal cancer patients were enrolled at 
one of 7 academic medical centers and 2 community hospitals in the U.S. and 
Canada [44].  To have at least 80% power to detect a clinically relevant 
difference in outcomes, a minimum of 225 pN0 patients were needed for this 
analysis.  In this study, lymph nodes were dissected from fresh colon and rectum 
specimens, and half of each was used for histopathology, while the other half 
was subjected to molecular analysis by GUCY2C qRT-PCR.  Indeed, more than 
85% of patients with histologically node-negative disease harbored occult 
metastases by molecular staging [44].  Thus, surprisingly, most patients staged as 
free of metastatic disease by histopathology have minimum residual disease in 
regional lymph nodes.  Further, 20.9% (CI, 15.8-26.8%) of patients with, but only 
6.3% (CI, 0.8-20.8%) without, occult metastases in regional lymph nodes 
developed recurrent disease (p=0.006) [44].  Indeed, occult metastases 
detected by molecular staging were associated with poorer prognosis and 
reduced disease-free survival in both stage I and II patients and in patients with 
colon and rectal cancers.  Importantly, time to recurrence and disease-free 
survival in patients with occult metastases were nearly identical to those of 
patients with stages IIIA and IIIB disease, highlighting the ability of these 
molecular approaches to upstage patients [44].  Moreover, multivariate analyses 
demonstrated that molecular staging provided the most powerful independent 
risk marker and patients who harbored occult metastases experienced shorter 
times to recurrence and reduced disease-free survival [44]. 
C.  Prognostic utility of molecular staging to individualize risk assessment.  
Occult metastases identified by molecular staging were an independent marker 
of risk of recurrent disease.  In these analyses, the vast majority of patients who 
were node-negative by histopathology were molecularly positive, suggesting 
that standard approaches under-estimate the incidence of metastases to 
regional lymph nodes in patients with colon cancer.  Interestingly, although a 
substantial fraction of node-negative patients harbored occult metastases by 
molecular staging, most of these patients did not develop recurrent disease 
[2,3].  To provide context, only about 50% of patients with stage III disease 
ultimately develop recurrent disease, and all have lymph node metastases 
identified by histology [2,3].  Resolving this apparent inconsistency relies on the 
concept that metastases in lymph nodes, independent of approaches 
employed for their detection, do not guarantee disease recurrence in any 
individual.  Rather, they help to stratify risk.  This study is the first to provide level 1 
evidence for the application of molecular staging of lymph nodes to 
individualize prognostic risk in cancer, employing an adequately powered, 
blinded, prospective multicenter clinical trial design.  Absence of data using this 
stringent study design has been one critical barrier limiting the translation of 
molecular diagnostics into patient-centric management paradigms that 
individualize prediction of risk and therapeutic response.  [4,5]. 
There is an established association between histologic tumor burden, assessed 
as the number of regional lymph nodes containing cancer cells, and risk of 
recurrent colorectal cancer [2,3,87-93].  In the context of sufficient numbers of 
lymph nodes for analysis, stage III patients in whom >4 lymph nodes harbor 
histologic metastases have rates of disease recurrence that are as much as 
100% greater than those patients with <3 lymph nodes containing tumor cells 
[2,3].  By extension, the precision of molecular staging also should benefit from 
appropriate lymph node collections, to most accurately incorporate an 
assessment of tumor burden into stratification of prognostic risk [4,5,21].  There is 
a presumption of an inverse relationship between the quantity of regional lymph 
nodes harboring molecularly-detected occult metastases and risk of recurrent 
disease.  In the cohort of histologically node-negative patients who provided 
≥12 lymph nodes [2,3] for molecular staging, patients with 0-3 nodes harboring 
occult metastases experienced minimum risk of developing recurrent disease 
[44].  In striking contrast, patients who had >4 lymph nodes infiltrated with occult 
metastases detected by molecular staging exhibited a prognostic risk that was 
identical to patients with stage III N1 colorectal cancer [44].  These 
considerations support the central importance of adequate regional lymph 
node collection to optimize molecular [4,5,21], as well as histological [2,3,90,91], 
detection of metastases to estimate tumor burden and improve risk stratification 
in colorectal cancer staging. 
While the exact number of lymph nodes necessary to optimize patient 
management has not been precisely clarified, the importance of sufficient 
lymph node collections to maximize the accuracy of staging and optimize 
outcomes for patient survival is a mainstay of patient management algorithms in 
colorectal cancer [2,3,87-93].  There is an emerging clinical paradigm involving 
the application of laparoscopy-assisted colectomy to manage patients with 
colon cancer [94].  It is noteworthy that this evolution in technique, which strives 
to reduce surgical morbidity and mortality, restricts collections of lymph nodes 
for staging [94].  While these innovations in surgical approaches improve intra-
operative management and post-operative recovery, the impact of reduced 
lymph node sampling on staging accuracy and, ultimately, patient survival has 
not been precisely quantified.  The emergence of molecular staging, offering an 
unprecedented opportunity to accurately evaluate patient prognosis and 
predict responses to chemotherapy, highlights the value of defining best 
practices for lymph node collection that optimize patient outcomes.  Defining 
the optimum number of nodes for molecular staging, in turn, will provide a rich 
source of data to inform the evolution of advances in surgical management.  It 
is envisioned that optimizing tissue requirements for molecular staging will drive 
restricted access surgical techniques to refine lymph node collections, 
producing integrated algorithms to evolve best management solutions for 
patients. 
In addition to the number of lymph nodes harboring cancer cells, there is an 
apparent association between the quantity of cancer cells in each lymph node, 
the burden of tumor metastases, and risk of disease recurrence [2,95].  Thus, 
metastatic foci of cancer cells in lymph nodes >0.2 mm are associated with 
increased risk of disease recurrence, while the association between individual 
tumor cells or nests <0.2 mm and prognosis is unclear [2].  The evolution of 
molecular staging using qRT-PCR provides a unique paradigm to specifically 
quantify metastases in tissues, including regional lymph nodes.  In that context, 
qRT-PCR offers unparalleled sensitivity for detection, with the capability of single 
cell identification in conjunction with analysis of optimum volumes of tissue to 
avoid sampling errors [96].  However, that improved sensitivity may translate into 
identification of occult tumor cells in regional lymph nodes that are below the 
limit for increased prognostic risk [2], restricting the specificity of molecular 
staging [44].  Future studies will need to identify the quantitative relationship 
between biomarker levels and prognostic risk, to assess the impact of tumor 
burden on optimizing prognostic sensitivity and specificity of molecular staging 
paradigms in cancer [44]. 
PERSPECTIVE 
To date, the most powerful indicator of prognosis and response to adjuvant 
chemotherapy in colorectal cancer is the identification of cancer cells in lymph 
nodes by histopathology [1-6,9,20-23].  Despite its central position in all staging 
paradigms, approaches to detecting lymph node metastases are inadequate. 
Up to 30% of patients with node-negative colon cancer succumb to disease 
recurrence, associated with occult metastases in lymph nodes undetected by 
conventional methods [2-5,21,24,42,43,97].  There is an unmet clinical need for 
new approaches to more precisely evaluate tumor metastases in regional 
lymph nodes in colon cancer patients.  Recently, a blinded, multicenter, 
prospective study demonstrated the utility of molecular staging to detect occult 
tumor metastases in regional lymph nodes to predict risk of disease recurrence 
[44].  Occult tumor metastases, defined by molecular staging, was the most 
powerful independent marker of risk of disease recurrence [44].  This represents 
the first level 1 evidence supporting the importance of occult metastases in 
regional lymph nodes in defining prognostic risk in patients with colon cancer 
[98].  These data establish a framework for the application of molecular staging 
in lymph nodes for individualizing prognostic risk assessment in patients with 
cancer. 
While these observations are a beginning, their translation into useful staging 
tools in cancer will require considerable analyses in the future.  These results will 
require confirmation in an independent cohort of patients with colorectal 
cancer, consistent with the emerging learn-confirm paradigm in biomarker 
translation, wherein integration into patient management algorithms require 
validation in independent populations [99-106].  Also, the exquisite sensitivity of 
qRT-PCR [96], reflecting optimum tissue sampling and ability to discriminate 
single cells, may reveal occult cancer cells in lymph nodes below the limit for 
clinical risk [2], restricting the specificity of molecular staging [44].  This is 
exemplified by the identification of occult metastases in the majority of patients, 
most of whom will remain free of disease [2].  The next step in the evolution of 
molecular staging will require a move beyond the simple presence of tumor 
cells to a standard that integrates the quantity of tumor burden across 
metastatic sites, including lymph nodes. Molecular staging, specifically the 
application of qRT-PCR, provides a remarkable platform to quantify occult 
cancer burden across all regional lymph nodes, and perhaps to more 
accurately stratify risk and predict therapeutic responses.   
Beyond prognosis, there is an established association between metastases in 
regional lymph node and the efficacy of chemotherapy in patients with 
colorectal cancer.  While adjuvant chemotherapy improves clinical outcomes 
in stage III patients, its impact on survival in patients that are node-negative by 
histology remains unclear [2,3,6,9,20,22,23,38].  This heterogeneity of therapeutic 
benefit in node-negative patients may, in part, reflect the inherent inaccuracy 
of staging by histopathology [4,5,21,24,42-44].  In contrast, molecular staging 
identified node-negative patients with a prognostic risk profile that closely 
matched stage III patients, a cohort that derives benefit from adjuvant 
chemotherapy [2,3].  These observations suggest that node-negative patients 
who harbor occult metastases detected by molecular staging also could 
benefit from adjuvant chemotherapy.  In the future, studies will examine 
whether occult lymph node metastases defined by molecular staging predicts 
chemotherapeutic efficacy.  These studies will assess if, in patients with occult 
metastases in regional lymph nodes identified by molecular staging, those 
treated with chemotherapy have improved clinical outcomes compared to 
those who are followed without treatment. 
SUMMARY 
Standard algorithms for staging colon cancer patients are largely based on a 
combination of histological evaluation of primary tumor and regional lymph 
nodes.  However, this gold standard underestimates the extent of disease, and 
25-30% of node-negative patients ultimately die of disease recurrence [107].  
Inadequacies of accepted optical staging algorithms, including tissue sampling 
and detection limits, can be overcome by molecular staging [44,107].  The 
molecular detection of occult lymph node metastases is a powerful 
independent indicator of prognostic risk of colorectal cancer recurrence 
[44,107].  Early prospective trials strongly suggest that molecular staging through 
comprehensive lymph node analysis quantifies tumor burden that identifies 
node-negative patients at increased risk of developing recurrent disease who 
might be candidates for adjuvant chemotherapy.   
Beyond lymph node analyses, evolving genomic platforms provide a rich source 
of prognostic and predictive information about primary tumors that can 
enhance staging algorithms optimizing outcomes that drive patient 
management.  Analyses of primary tumors to define gene expression and 
epigenetic profiles, disease-associated mutations in oncogenes or tumor 
suppressors, and metabolomic and proteomic signatures that individualize 
assessments of recurrence risk, responses to adjuvant chemotherapy, and 
biologically-targeted treatments are enhancing the prognostic and predictive 
management of cancer patients [108-112].  However, defining the prognostic 
and predictive character of primary tumors by molecular analyses may be most 
relevant in the context of whether tumors have metastasized.  A primary tumor 
with a molecular signature suggesting a poor prognosis might represent less risk 
to the patient if that tumor was completely resected at the time of surgery, 
before metastases occurred.  Thus, emerging technology platforms defining 
prognosis and prediction for clinical management employing molecular 
analyses of primary tumors might produce the greatest benefit when applied to 
patients harboring occult nodal metastases, rather than to those free of 
metastatic disease.  Here, molecular staging offers a unique opportunity to 
prioritize complex and expensive molecular analyses of primary tumors to 
optimize cost-effective patient management [44].  In the future, trials will 
examine the applicability of reflexed analytical paradigms in which all 
histologically node-negative patients undergo molecular staging, to determine 
whether there is clinically important occult lymph node metastases, followed by 
further molecular testing of primary tumors only for patients at increased 
prognostic risk, to identify therapies personalized to the biology of their individual 
malignancies [113]. 
It is important to consider that qRT-PCR is an evolving technical platform that 
primarily remains the domain of centralized specialty laboratories, and has not 
yet been broadly distributed to most academic and community medical 
centers.  These realities raise the important question concerning limitations to 
implementation of molecular staging as a clinical standard central to practice 
guidelines.  In that regard, molecular diagnostics is an emerging $14 billion dollar 
business, that is increasing at a rate exceeding 10% annually [114,115].  Indeed, 
the number of esoteric molecular diagnostic tests approved by the FDA each 
year is growing aggressively, from 72 in 2006 to 134 in 2009 [116].  Additionally, 
the number of home brew molecular diagnostic tests, developed in individual 
laboratories, was in excess of 1,400 in 2009 [117].  These considerations suggest 
that molecular diagnostic tests, including molecular staging, available to 
clinicians and patients will grow.  In the near term, central laboratory 
performance sites provide the depth of experience and validated technology 
platforms that align with requirements for FDA regulatory performance and CMS 
reimbursement.  They will ultimately support the most informative approaches to 
incorporate molecular staging paradigms into patient-centered algorithms for 
disease management. 
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Figure Legends 
Figure 1.  Identification of occult tumor metastases in lymph nodes employing 
marker-specific quantitative RT-PCR.  At the time of colectomy, regional lymph 
nodes are harvested from tumor-associated mesenteric structures for staging.  In 
the canonical paradigm, these lymph nodes are formalin-fixed and paraffin-
embedded and thin sections are reviewed by standard histopathology to 
identify metastatic tumors cells.  This approach is associated with limitations in 
sampling, in which only a small portion of the available tissue is subject to 
review.  Also, there is a limitation in sensitivity, in which the pathologist can 
reliably identify only one tumor cell in 200 normal cells in a lymph node 
specimen.  Together, these limitations result in under-staging of patients, in which 
lymph nodes apparently free of disease by standard histopathology (pN0) 
actually harbor occult metastases [pN0(mol+)].  One approach to identify 
lymph nodes harboring occult metastases that escape detection by the 
standard paradigm is to couple a sensitive and specific tumor marker, like GCC, 
to a powerful amplification technology, like RT-PCR.  This molecular approach 
overcomes the sampling limitation of standard histopathology, since mRNA from 
the entire available specimen is extracted and sampled for expression of the 
tumor-associated marker.  Moreover, RT-PCR is exquisitely sensitive and can 
detect one tumor cell in one million normal cells, unlike standard histopathology. 
